NPS Pharmaceuticals (NPSP) Jumps On Positive Analyst Comments Ahead of AdComm

NPS Pharmaceuticals Inc. (NASDAQ: NPSP) is higher Thursday following positive comments from analyst at Jefferies about an expected positive Gattex AdComm panel on 10/16/12.

"EU approval of teduglutide (Gattex/Revestive) without restriction/minimal requirement in early Sept provides some comfort ahead of FDA panel on 10/16," the analyst comments. "Expert expects ~<10K pts on therapy at peak (~in-line) but gradual uptake (FY13/FY14 cons sales #s too high). However, we note gradual uptake is widely expected among investors; and its 2nd product Natpara BLA filing/approval will support further valuation upside."

The firm reiterated their Buy rating and price target of $13.00.

For an analyst ratings summary and ratings history on NPS Pharmaceuticals Inc. click here. For more ratings news on NPS Pharmaceuticals Inc. click here.

Shares of NPS Pharmaceuticals Inc. closed at $8.98 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Jefferies on Five Below (FIVE): 'Our latest channel checks reinforce our view that FIVE's momentum extends well beyond viral Squish trends'
• SoundThinking (SSTI) PT Lowered to $8 at Cantor Fitzgerald
• UBS Reiterates Buy Rating on Hilton Worldwide (HLT)